Tag: US pharma

US Court Enters Consent Decree against PharMedium

fda
U.S. District Judge Virginia M. Kendall for the Northern District of Illinois entered a consent decree of permanent injunction between the United States and PharMedium Services, LLC, headquartered in ...

Beiersdorf Agreed to Buy Bayer Coppertone

Beiersdorf and Bayer announced that Beiersdorf has entered into a definitive agreement to buy the Coppertone™ business from Bayer for a purchase price of 550 million U.S. dollars.  Founded in 1944,...

ROMEG Reports FDA Approval for Gout Flares Solution

ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the U.S. Food and Drug Administration (FD...

Big Pharma Answered for High Prices

U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate...

CMS Proposed Coverage of New Form of Cancer Therapy

Proposed decision would provide nationwide consistency in CMS’s coverage of the innovative new cancer therapy, to improve patient access and ensure appropriate evidence generation. The Centers for ...

Leading Manufacturer Choose Paperless Validation

ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), announced that a New Jersey-based leading contract manufacturer of pharmaceutical drugs has chosen Val...

PhRMA Criticize Damaging Price Control in Some Countries

The Pharmaceutical Research and Manufacturers of America (PhRMA) urged the Office of the United States Trade Representative (USTR) to take immediate action to address serious and growing market access...

Big Pharma to Testify in High Drug Pricing Case

While congressional scrutiny on drug pricing is nothing new, the prospect of some of the pharmaceutical industry's highest-profile CEOs testifying on the issue will make for a must-watch event. In ...

Biocept Launches RUO Liquid Biopsy Kits

Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, ann...

US Tries First Digital Oncology Drugs

Cancer patients in the US are trialling digital oncology drugs for the first time, collecting data on patients in a bid to improve outcomes and help adherence. The new technology from Proteus Digit...

TrakCel and Quick Partner for Cell and Gene Therapies Tracking

On Jan. 17, 2019, TrakCel, a UK-based developer of cell and gene therapy supply-chain tracking and orchestration systems software, and The Quick Life Science Group, a US-based provider of time- and te...

AstraZeneca and Ironwood’s IBS-C Drug Approved in China

Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults with the condition. The good news coincides with big chang...

Generic for Alzheimer’s and Parkinson’s Approved by FDA

The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to A...

GE Healthcare and VUMC to Develop New DIagnostic Tools for Cancer Treatment

New diagnostic tools will be developed by GE Healthcare and Vanderbilt University Medical Centre (VUMC) to help make cancer immunotherapies safer and more accurate. As part of a five-year partnersh...

AbbVie and Tizona to Develop Antibody for Cancer Treatment

AbbVie, a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc., a privately held immunotherapy company, announced on Jan. 3, 2019 that they have entered into a global, strate...

FDA Granted Priority Review Non-Opioid for Postoperative Pain

Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient...